Prosty Connor, Katergi Khaled, Papenburg Jesse, Lawandi Alexander, Lee Todd C, Shi Hao, Burnham Philip, Swem Lee, Routy Bertrand, Yansouni Cedric P, Cheng Matthew P
Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
eGastroenterology. 2024 Sep 10;2(3):e100086. doi: 10.1136/egastro-2024-100086. eCollection 2024 Sep.
Composed of an elaborate ecosystem of bacteria, fungi, viruses and protozoa residing in the human digestive tract, the gut microbiome influences metabolism, immune modulation, bile acid homeostasis and host defence. Through observational and preclinical data, the gut microbiome has been implicated in the pathogenesis of a spectrum of chronic diseases ranging from psychiatric to gastrointestinal in nature. Until recently, the lack of unequivocal evidence supporting a causal link between gut microbiome and human health outcomes incited controversy regarding its significance. However, recent randomised controlled trial (RCT) evidence in conditions, such as infection cancer immunotherapy and ulcerative colitis, has supported a causal relationship and has underscored the potential of the microbiome as a therapeutic target. This review delineates the RCT evidence substantiating the potential for a causal relationship between the gut microbiome and human health outcomes, the seminal observational evidence that preceded these RCTs and the remaining knowledge gaps.
肠道微生物群由存在于人类消化道中的细菌、真菌、病毒和原生动物组成的复杂生态系统构成,它影响新陈代谢、免疫调节、胆汁酸稳态和宿主防御。通过观察性和临床前数据,肠道微生物群已被认为与一系列从精神性到胃肠道性质的慢性疾病的发病机制有关。直到最近,由于缺乏明确证据支持肠道微生物群与人类健康结果之间的因果关系,引发了关于其重要性的争议。然而,最近在感染、癌症免疫治疗和溃疡性结肠炎等病症中的随机对照试验(RCT)证据支持了因果关系,并强调了微生物群作为治疗靶点的潜力。本综述阐述了证实肠道微生物群与人类健康结果之间存在因果关系可能性的RCT证据、这些RCT之前的重要观察性证据以及其余的知识空白。